The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | The potential of translational research to impact the diagnosis & management of B-cell lymphomas
In this video, Christian Buske, MD, University Hospital Ulm, Ulm, Germany, discusses the potential of translational research to impact the diagnosis and management of B-cell lymphomas, including marginal zone lymphoma (MZL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). Prof. Buske expresses his excitement about the development of liquid biopsy, which enables a better understanding of the clonal composition of a patient’s disease. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, I think there’s a lot ongoing in classifying marginal zone lymphoma from a molecular side to understand prognostication of different subtypes. But what I think is probably most exciting is the development of liquid biopsy in all these B-cell lymphomas. So that we are able from peripheral blood to monitor patients in the sense that we know the molecular composition of these patients and how these patients react to treatment, also on a clonal or subclonal level, and how the clonal composition looks like when the patients have a relapse...
Yeah, I think there’s a lot ongoing in classifying marginal zone lymphoma from a molecular side to understand prognostication of different subtypes. But what I think is probably most exciting is the development of liquid biopsy in all these B-cell lymphomas. So that we are able from peripheral blood to monitor patients in the sense that we know the molecular composition of these patients and how these patients react to treatment, also on a clonal or subclonal level, and how the clonal composition looks like when the patients have a relapse. So I think this let’s say translational research has a I think major impact on treatment, adaptation, treatment intensification, de-escalation in the future, not only in marginal zone, but in many other lymphomas such as Waldenstrom’s or follicular lymphoma, mantle cell lymphoma and so on.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
